|
Volumn 424, Issue 6945, 2003, Pages 121-126
|
SARS: What have we learned?
[No Author Info available]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
DISEASE CONTROL;
DISEASES;
VIRUSES;
PNEUMONIA;
HEALTH CARE;
GLYCYRRHIZA EXTRACT;
GLYCYRRHIZIC ACID;
VIRUS VACCINE;
ANTIVIRUS AGENT;
SEVERE ACUTE RESPIRATORY SYNDROME;
VIRAL DISEASE;
CAUSE OF DEATH;
CLINICAL FEATURE;
CORONAVIRUS;
COUGHING;
DRUG SAFETY;
EPIDEMIC;
FEVER;
GENE MUTATION;
GENE SEQUENCE;
HUMAN;
MASS COMMUNICATION;
MORTALITY;
PATIENT CARE;
POLYMERASE CHAIN REACTION;
PRIORITY JOURNAL;
PUBLIC HEALTH;
RECURRENT DISEASE;
RESPIRATORY TRACT INFECTION;
SARS CORONAVIRUS;
SEVERE ACURE RESPIRATORY SYNDROME;
SHORT SURVEY;
SYMPTOM;
VIRUS GENOME;
VIRUS PNEUMONIA;
VIRUS TRANSMISSION;
WORLD HEALTH ORGANIZATION;
ANIMAL;
ARTICLE;
CHINA;
COMMUNICABLE DISEASE;
GENETICS;
HEALTH CARE PLANNING;
MUTATION;
SEVERE ACUTE RESPIRATORY SYNDROME;
CORONAVIRUS;
GLYCYRRHIZA;
RNA VIRUSES;
SARS CORONAVIRUS;
ANIMALS;
ANTIVIRAL AGENTS;
CHINA;
COMMUNICABLE DISEASES, EMERGING;
HEALTH PLANNING;
HUMANS;
MUTATION;
SARS VIRUS;
SEVERE ACUTE RESPIRATORY SYNDROME;
VIRAL VACCINES;
|
EID: 0037819454
PISSN: 00280836
EISSN: None
Source Type: Journal
DOI: 10.1038/424121a Document Type: Short Survey |
Times cited : (69)
|
References (22)
|